BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.

CONTEXT How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. OBJECTIVE To study whether BRAF V600E affected LNM-associated mortality in PTC. DESIGN, SETTING, PARTICIPANTS We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 (IQR 35-58) years and median follow-up time of 58 (IQR 26-107) months. RESULTS Overall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAFV600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAFV600E patients; mortality rates were 2/659 (0.3%) versus 4/321 (1.2%) in non-LNM versus LNM patients (P=0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAFV600E CPTC, morality rates were 7/515 (1.4%) versus 28/363 (7.7%) in non-LNM versus LNM patients (P<0.001), corresponding to HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAFV600E versus absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism. CONCLUSIONS LNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance.

[1]  N. Cipriani.  Prognostic Parameters in Differentiated Thyroid Carcinomas. , 2019, Surgical pathology clinics.

[2]  M. Milas,et al.  Management of Nodal Disease in Thyroid Cancer. , 2019, The Surgical clinics of North America.

[3]  D. Kodetová,et al.  Somatic genetic alterations in a large cohort of pediatric thyroid nodules , 2019, Endocrine connections.

[4]  Douglas B. Evans,et al.  Thyroid cancer in adolescents and young adults , 2018, Pediatric blood & cancer.

[5]  E. Loh,et al.  Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis , 2018, World Journal of Surgery.

[6]  L. Yip,et al.  Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Fan Yang,et al.  BRAFV600E mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account , 2017, Oncology letters.

[8]  R. Mahfouz,et al.  BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases , 2017, Scientific Reports.

[9]  Tao Zhang,et al.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality , 2017, JAMA oncology.

[10]  M. Xing,et al.  Recent incidences and differential trends of thyroid cancer in the USA. , 2016, Endocrine-related cancer.

[11]  Tae Yong Kim,et al.  Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. , 2016, The Journal of clinical endocrinology and metabolism.

[12]  G. Sergi,et al.  Prognostic impact of extra‐nodal extension in thyroid cancer: A meta‐analysis , 2015, Journal of surgical oncology.

[13]  M. Luster,et al.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[14]  J. Bishop,et al.  BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Baade,et al.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer , 2014, Endocrine.

[16]  S. Bose,et al.  BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. , 2014, Human pathology.

[17]  J. Bishop,et al.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.

[18]  P. Ladenson,et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.

[19]  M. Schlumberger,et al.  Progress in molecular-based management of differentiated thyroid cancer , 2013, The Lancet.

[20]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[21]  J. Ricarte-Filho,et al.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. , 2011, Thyroid : official journal of the American Thyroid Association.

[22]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[23]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[24]  L. Rotstein.  The role of lymphadenectomy in the management of papillary carcinoma of the thyroid , 2009, Journal of surgical oncology.

[25]  A. Shaha.  Editorial: Complications of Neck Dissection for Thyroid Cancer , 2007, Annals of Surgical Oncology.

[26]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[27]  Guojun Wu,et al.  High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. , 2005, The Journal of clinical endocrinology and metabolism.

[28]  David D. Smith,et al.  The Implication of Lymph Node Metastasis on Survival in Patients with Well-Differentiated Thyroid Cancer , 2005, The American surgeon.

[29]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[30]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[31]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[32]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[33]  J. Chmiel,et al.  Survival discriminants for differentiated thyroid cancer. , 1990, American journal of surgery.

[34]  B. Cady,et al.  Current results of conservative surgery for differentiated thyroid carcinoma , 1986, World Journal of Surgery.

[35]  J. Fagin,et al.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jie Gao,et al.  Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. , 2015, International journal of clinical and experimental pathology.

[37]  S. Sherman.  Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. , 1999, Seminars in surgical oncology.

[38]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .

[39]  I. Hay,et al.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. , 1996, Surgical oncology clinics of North America.